A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

UCB Pharma1 个研究点分布在 1 个国家开始时间: 2004年1月最近更新: 2014年10月20日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方: UCB Pharma
试验地点: 1

研究概览研究设计入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson's disease.

详细描述

See approved Package Insert for Adverse Event information.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Stable Parkinson's Disease

排除标准

•Not using carbidopa/levodopa tablets

研究者

发起方

UCB Pharma

申办方类型

Industry

研究点 (1)

Loading locations...

相似试验

进行中（未招募）

2 期

Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)Systemic Lupus Erythematosus

NCT04179032GlaxoSmithKline25

已完成

3 期

CORAL XT - Open-label Extension Trial of the CORAL TrialPainNeoplasmsChronic Pain

NCT02031432Tris Pharma, Inc.76

已完成

1 期

An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)Infertility

NCT00647933Organon and Co24

终止

3 期

Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson DiseaseWilson Disease

NCT05047523Alexion Pharmaceuticals, Inc.40

招募中

2 期

The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular HemorrhageCommunicating HydrocephalusCerebral Intraventricular HemorrhageSecondary Normal Pressure HydrocephalusPost Hemorrhagic Hydrocephalus

NCT06563817Beijing Tiantan Hospital53